Table 4. Adverse events.
| Adverse events | Total cohort (n = 88)% | OFI-C (n = 52)% | OFI-Y (n = 16)% | OTI (n = 20)% |
|---|---|---|---|---|
| Infection | ||||
| • Grade 1 | 11 (13%) | 4 (8%) | 3 (19%) | 4 (20%) |
| • Grade 2 | 10 (11%) | 4 (8%) | 2 (13%) | 4 (20%) |
| • Grade 3 | - | - | - | - |
| • Grade 4 | 1 (1%) | - | - | 1 (5%) |
| Bone breakage | 2 (2%) | 2 (4%) | - | - |
| Implant breakage | ||||
| • Intramedullary stem | - | - | - | - |
| • DCA | 4 (5%) | 1 (2%) | 2 (13%) | 1 (5%) |
| Aseptic loosening | - | - | - | - |
| Stoma redundant tissue | 1 (1%) | - | 1 (6%) | - |
| Death | - | - | - | - |
N: participants, OFI-C: Osseointegration femur implant curved type, OFI-Y: Osseointegration femur implant gamma type, OTI: Osseointegration tibia implant, DCA: Dual cone adapter. - = 0 (0%)